Genetic Variants Predict Response to Hepatitis C Treatment
Author Information
Author(s): Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J. Armstrong, Kate S. O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J. Dore, William L. Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Müller, Emma Hammond, David Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J. Stewart, Jacob George, David R. Booth
Primary Institution: University of Sydney
Hypothesis
Can the combined effect of IL28B, HLA-C, and KIR gene variants improve the prediction of treatment response in chronic hepatitis C patients?
Conclusion
Genotyping for IL28B, HLA-C, and KIR genes improves prediction of HCV treatment response.
Supporting Evidence
- IL28B SNP rs8099917 'G' was associated with absence of treatment-induced clearance.
- HLA-C C2C2 genotype was over-represented in patients who failed treatment.
- Prediction of treatment failure improved from 66% with IL28B to 80% using both genes.
Takeaway
Scientists found that checking certain genes can help doctors know if hepatitis C patients will respond to treatment better.
Methodology
The study involved genotyping chronic hepatitis C patients for specific gene variants and analyzing their treatment outcomes.
Limitations
The findings need confirmation in other ethnic groups and populations.
Participant Demographics
All participants were Europeans or of European descent.
Statistical Information
P-Value
1.27×10−8
Confidence Interval
1.67–2.88
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website